Atopic Dermatitis

Questions discussed in this category

How do you approach treating patients who develop psoriasis while on Dupixent?

Do you start/trial them on another biologic or just rely on topical therapies?

2 Answers available

Is the timing of childhood eczema onset useful as a prognostic factor in predicting food allergy tolerance?

2 Answers available

What is your approach to managing moderate to severe atopic dermatitis in pregnancy?

2 Answers available

What is your approach for female patients with severe atopic dermatitis well controlled on Dupixent planning to conceive or already pregnant?

1 Answer available

Which patient factors drive you to pursue patch testing in the workup of chronic hand eczema?

1 Answer available

Does baseline facial dermatitis in a patient with AD cause hesitation when starting Dupixent due to conjunctivitis-related complications, especially when there are many available options?

2 Answers available

When would you pursue genetic testing for severe recalcitrant atopic dermatitis?

1 Answer available

How do you manage atopic dermatitis in patients who have failed dupilumab?

2 Answers available

What is your approach for workup and management of prurigo nodularis?

2 Answers available

Do all patients initiating omalizumab need to have it administered in a healthcare setting?

1 Answer available

What criteria do you utilize in deciding between different jak inhibitors for atopic dermatitis?

Abrocitinib (cibinqo) vs upadacitinib (rinvoq)

1 Answer available

What therapies have you found most effective in providing rapid improvement in patients with erythrodermic atopic dermatitis?

2 Answers available

Have you seen CD30+ lymphoproliferative skin lesions with Upadacitinib treatment of atopic dermatitis?

1 Answer available

What is the longest interval that you have been able to stretch a biologic before losing efficacy?

Naturally, this is subject a number of factors and is likely patient-dependent. We also recognize that the way clinical trials have been designed lead...

2 Answers available

Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?

1 Answer available

Do you utilize AIT for atopic dermatitis if there is no AR present?

4 Answers available

How does omalizumab play a role in the armamentarium of atopic dermatitis?

1 Answer available

How do you decide between IL-4/IL-13 blockade (dupixent) versus IL-13 blockade only (Adbry) as treatments for Atopic Dermatitis?

3 Answers available

How do you approach patients that develop atopic dermatitis while on biologics for psoriasis?

I have an elderly patient with a history of biopsy-proven psoriasis on IL-17 biologic therapy. She has developed an intense itch without a primary ras...

1 Answer available

Would you consider adding dupilumab to adalimumab (or other monoclonal antibodies) in a patient who has RA and refractory atopic dermatitis and already is on MTX 25 mg weekly?

2 Answers available

What treatment modalities have you had success in treating perioral or periorbital dermatitis when they have failed Topical calcineurin inhibitor and oral antibiotics?

2 Answers available

Do you have to remove gold dental crowns if patch testing reveals a gold allergy?

1 Answer available

Do you prescribe fluocinolone in peanut oil in patients with peanut allergies?

3 Answers available

How do you perform patch testing in patients who are allergic to adhesives?

1 Answer available

Does Dupixent interfere with patch testing?

https://www.jaad.org/action/showPdf?pii=S0190-9622%2824%2903329-2

1 Answer available

What labs do you order to monitor patients on JAK1 inhibitiors (abrocitinib or upadacitinib)?

How often do you order labs?

1 Answer available

When do you prescribe topical JAK inhibitors for adult patients with atopic dermatitis?

Do you prescribe JAK inhibitors as first-line treatments? Do you perform any lab monitoring?

1 Answer available

When do you refer pediatric patients with eczema to an allergist?

Are there cases where food or environmental allergies significantly worsen eczema in children?

1 Answer available

Where do oral and topical JAK inhibitors fit into your treatment algorithm and approach to atopic dermatitis?

2 Answers available

With the approval of oral JAK inhibitors such as Upadacitinib for atopic dermatitis, how are you considering its safety profile in comparison to traditional immunosuppressants such as prednisone, methotrexate, azathioprine, and mycophenolate?

Especially in the setting of these being more narrow acting than tofacitinib, should we consider them safer than our old drugs?

2 Answers available

What is your approach to treating patients with dupilumab induced facial redness?

2 Answers available

Papers discussed in this category

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2023 Feb 11

Eczematized psoriasis - a frequent but often neglected variant of plaque psoriasis.

Journal of the American Academy of Dermatology, 2003-04

Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive.

The Journal of experimental medicine, 2010 May 03

Regulation of learning and memory by meningeal immunity: a key role for IL-4.

Journal of immunology (Baltimore, Md. : 1950), 2017 Feb 15

IL-13-Mediated Regulation of Learning and Memory.

Nature communications, 2023 Jan 13

Interleukin-13 and its receptor are synaptic proteins involved in plasticity and neuroprotection.

Cellular & molecular immunology, 2023 Jul 10

Type 2 immunity in the brain and brain borders.

JAAD case reports, 2019 May 08

Recalcitrant prurigo nodularis treated successfully with dupilumab.

Dermatitis : contact, atopic, occupational, drug, 2020 Jan/Feb

Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis.

Journal of the American Academy of Dermatology, 2025 Oct 29

International Multi-Center Case Series of Gestational Dupilumab Exposure in the Treatment of Atopic Dermatitis: Maternal Complications and Fetal Outcomes.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2025 Sep

Bridging the gap: Treatment of atopic dermatitis with dupilumab during pregnancy.

International journal of dermatology, 2024 Aug 01

Pregnancy and breastfeeding outcome in patients with atopic dermatitis treated with dupilumab: the clinical experience of three centers.

The Journal of allergy and clinical immunology, 2022 Sep 30

Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2023 Dec 18

Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2019 Feb 04

Omalizumab for atopic dermatitis: evidence for and against its use.

The Journal of allergy and clinical immunology, 2016 Jul 14

Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis.

JAMA pediatrics, 2020 Jan 01

Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial.

Nature communications, 2024 Apr 02

Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2015 Jan

Which infants with eczema are at risk of food allergy? Results from a population-based cohort.

JAMA network open, 2025 Jun 02

Phenotypes of Atopic Dermatitis and Development of Allergic Diseases.

Related Topics